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Abstract
Aims/hypothesis The reasons underlying a greater association of premature mortality with early-onset type 2 diabetes
relative to late-onset disease are unclear. We evaluated the clinical characteristics at type 2 diabetes diagnosis and the
broad trajectories in cardiometabolic risk factors over the initial years following diagnosis in relation to age at
diagnosis.
Methods Our cohort consisted of 100,606 individuals with newly diagnosed type 2 diabetes enrolled in the Swedish National
Diabetes Register from 2002 to 2012. The average follow-up time was 2.8 years. Analyses were performed using a linear mixed-
effects model for continuous risk factors and a mixed generalised linear model with a logistic link function for dichotomous risk
factors.
Results The individuals diagnosed at the youngest age (18–44 years) were more often male and had the highest BMI (mean of
33.4 kg/m2) at diagnosis and during follow-up compared with all other groups (those diagnosed at 45–59 years, 60–74 years and
≥75 years; p < 0.05), being ~5 kg/m2 higher than the oldest group. Although HbA1c patterns were similar between all age groups,
there was a difference of about 5 mmol/mol (0.45%) between the two groups at 8 years post-diagnosis (p < 0.05). Additionally,
individuals diagnosed younger had ~0.7 mmol/l higher triacylglycerol, and ~0.2 mmol/l lower HDL-cholesterol levels at
diagnosis relative to the oldest group. Such differences continued for several years post diagnosis. Yet, although more of these
younger individuals were receiving oral glucose-lowering agents, other cardioprotective therapies were prescribed less often in
this group. Differences in BMI, blood glucose and lipid levels remained with adjustment for potential confounders, including
marital status, education and country of birth, and, where relevant, differential treatments by age, and in those with at least 5 years
of follow-up.
Conclusions/interpretation Individuals who develop type 2 diabetes at a younger age are more frequently obese, display a more
adverse lipid profile, have higher HbA1c and a faster deterioration in glycaemic control compared with individuals who develop
diabetes later in life. These differences largely remain for several years after diagnosis and support the notion that early-onset type
2 diabetes may be a more pathogenic condition than late-onset disease.
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Introduction
The prevalence of diabetes mellitus has been increasing dur-
ing the past few decades with rapid rises in incidence in the
1990s and early 2000s [1, 2]. Type 2 diabetes is now more
frequently diagnosed in young adults and adolescents [3–5].
The obvious reason for this is increasing obesity among young
people. In the 1990s, obesity increased by 70% in people aged
18–29 years in the USA and, in the same decade, type 2
diabetes also increased by 70% in people aged 30–39 years
[2, 6]. Consequently, in recent years, type 2 diabetes has
sometimes been categorised as early-onset diabetes, i.e. peo-
ple diagnosed before the age of 45, and later-onset (or usual-
onset), i.e. people diagnosed ≥45 years of age [7].
Cardiovascular disease (CVD) is a major cause of mortality
in individuals with type 2 diabetes [8, 9]. From a cardiovascular
perspective, early-onset type 2 diabetes appears to be more ag-
gressive than later-onset disease. For example, when younger
people are diagnosed with type 2 diabetes they often already
have several risk factors for developing CVD [10–12]. Our
research group recently confirmed that younger age at type 2
diabetes diagnosis and poor glycaemic control were individual-
ly correlated with excess risk of death from any cause and from
CVD [13]. Furthermore, others have shown that early-onset
type 2 diabetes is more strongly pathogenic than type 1 diabetes
[14]. However, the reasons behind the higher risk of complica-
tions in early-onset type 2 diabetes are not fully understood.
Whilst there are some data to suggest that obesity and dif-
ferential changes in blood glucose may be operating in early-
onset type 2 diabetes, a comprehensive study examining ma-
jor CVD risk factors according to age at diagnosis, as well as
examining subsequent trends in risk factor control, is lacking.
Therefore, the aims of this study were to evaluate, in relation
to age at diagnosis: (1) clinical characteristics at diagnosis; (2)
trajectories (time trends) in CVD risk factors over the initial
years following type 2 diabetes diagnosis; and (3) whether any
apparent differences were inter-related (e.g. BMI vs lipids) or
could be easily explained by differential treatments (e.g.
statins and glucose-lowering drugs).
Methods
The primary aim of this observational study was to describe
how CVD risk factors change over time from diagnosis of
type 2 diabetes depending on age at diagnosis in using data
Research in context
What is already known about this subject?
What is the key question?
What are the new findings?
How might this impact on clinical practice in the foreseeable future?
Developing type 2 diabetes at a younger age may be more harmful in terms of risk of complications compared
with developing it much later in life
For example, we know that developing diabetes at a younger age is associated with higher obesity rates than
when diabetes develops later in life, but we have less information about other risk factors
Which risk factors linked to diabetes complications are more adverse in people developing diabetes at younger
ages and what are the trajectories of such risk factors over the first few years of diagnosis compared with
people who develop diabetes at an older age?
People who develop diabetes at a younger age are more obese and have worse blood glucose and lipid levels
compared with those who develop diabetes when older
Such differences in risk factors persist for several years after diagnosis
The differences in blood glucose were notable since more, not fewer, of the participants with younger-onset
diabetes were on blood-glucose lowering therapy
Our findings support the need for more aggressive management of obesity, blood glucose levels and
dyslipidaemia in younger people with type 2 diabetes to reduce their longer-term heightened
risks of complications
•
•
•
•
•
•
•
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from the Swedish National Diabetes Register (NDR). The
NDR was launched in 1996 as a nationwide clinical quality
register that aims to support and monitor improvements in the
quality of diabetes care. It now contains clinical data on about
90% of individuals aged ≥18 years with diabetes (type 1 and
type 2) in Sweden. Before inclusion into the NDR informed
consent has to be provided by each participant [15, 16].
Ethical approval to conduct this study was acquired from the
Regional Ethical Review Board in Gothenburg, Sweden.
Study population Individuals with newly diagnosed type 2 di-
abetes who had at least one listing in the NDR between 1
January 2002 and 31 December 2012 were identified. Type 2
diabetes was defined on the basis of epidemiological data: indi-
viduals receiving dietary treatment only, oral glucose-lowering
agents only, or those diagnosed at ≥40 years of age receiving
insulin therapy or insulin and oral glucose-lowering agents. In
Sweden, the WHO diagnostic criteria are used to diagnose dia-
betes [17]. All individuals who did not have information on age
at diagnosis of diabetes were excluded. We assessed potential
misclassification bias by comparing the concordance between
the epidemiological definitions of type 2 diabetes with the clini-
cian’s classification of diabetes type (which is also available in
the NDR); we confirmed that 97% of our cohort were also clas-
sified as type 2 diabetes by their clinician.
Newly diagnosed individuals in each age category (age at
type 2 diabetes diagnosis) were followed until death or end of
follow-up on 31 December 2012. The median follow-up was
2.22 years (interquartile range, 0.80–4.31 years; maximum,
10.9 years; mean follow-up was 2.8 years). Thus, we studied
individuals who were enrolled in the NDR in the same year
that they were diagnosed and we followed them for up to
10 years. Reporting into the NDR is performed approximately
annually, which results in multiple measurements being
available for each participant. Our final cohort consisted of
100,606 individuals contributing 679,420 observations. We
categorised the cohort into the following four age groups
(age at type 2 diabetes diagnosis was equal to actual age
owing to the inclusion criteria): 18–44 years, 45–59 years,
60–74 years and ≥75 years.
Details on variables Glycaemic control was estimated based
on HbA1c measurements, which were calibrated nationwide
with the HPLCMono-Smethod and converted intommol/mol
according to the International Federation of Clinical
Chemistry [18]. Systolic BP (SBP) and diastolic BP (DBP)
were measured in mmHg. BMI was calculated as weight (kg)
divided by the height squared (m2). Blood lipid profile was
estimated based on LDL-cholesterol, HDL-cholesterol, triac-
ylglycerols and total cholesterol measurements, all measured
in mmol/l. Serum creatinine was measured in μmol/l and
eGFR was carried out by the Modification of Diet in Renal
Disease (MDRD) study equation.
Microalbuminuria was defined as two positive results for
three samples obtained within 1 year of each other, with an
albumin/creatinine ratio of 3–30 mg/mmol or a urinary albu-
min clearance of 20–200 μg/min. All variables were assessed
from 2002 to 2012. Initial medication data were obtained
within 3 months of diagnosis.
Statistical analysis Continuous dependent variables (e.g. SBP)
were analysed using a mixed-effects model that incorporated a
random participant effect, fixed effects of age group, time, and
a time by age group interaction where time was a categorical
variable. This allowed for separate estimates of time trends for
each age group. HbA1c observations were analysed starting
1 year after diagnosis to avoid the rapid drop in HbA1c com-
monly seen during the first year. The models contained adjust-
ment factors, such as sex, BMI, smoking and concomitant
treatment subject to convergence, as well as, where relevant,
socioeconomic (marital status and education) measures and
country of birth (categorised as in Table 1). Complete infor-
mation on other adjustment variables is available in the ESM
Table 1. Themixed-repeated-measures model handles missing
data under the assumption of missing at random without rely-
ing on crude imputation techniques, such as last value carried
forward, and is therefore less prone to bias.
The graphical representation of the data is based on esti-
mated and observed yearly averages with 95% CI for up to
8 years after diagnosis. Sensitivity analyses, adjusted for con-
founders, were conducted for individuals with at least 5 years
of follow-up (ESM Fig. 2a–e), which included adjustments for
the confounders shown in ESM Table 1. Further sensitivity
analyses were additionally adjusted for marital status, educa-
tion and country of birth.
A p value <0.05 was considered to be statistically signifi-
cant and, since no adjustment for multiple comparisons has
been made, the interpretations should focus on the overall
patterns rather than the outcomes of single hypothesis tests.
All statistical analyses were conducted with SAS (version 9.4;
www.sas.com/en_gb/software/sas9.html, accessed 10
November 2017) and R (version 3.2.3) (https://www.rstudio.
com/products/rstudio/download/; https://cran.hafro.is/; both
accessed 10 November 2017).
Results
Baseline characteristics and risk factor differences Table 1
shows baseline characteristics in the overall cohort stratified
by age group. Baseline was defined as the participant’s first
observation in the NDR at year of diagnosis. Women represent-
ed 44.7% of the total cohort. The mean age (years) in each age
group was 38.3, 53.1, 66.2 and 80.4. At diagnosis, the youngest
group contained proportionately more men, had a higher mean
BMI by about 5 kg/m2 and a higher mean HbA1c of ~3 mmol/
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mol (0.27%) compared with the oldest group. The youngest
group also had the highest triacylglycerol and the lowest
HDL-cholesterol levels of all the groups. However, this group
had the lowest SBP and one of the highest DBP compared with
the other age groups. In terms of treatments, statin use was
lowest in youngest age group, being almost three times lower
than rates of use in the 60–74 years age group. In contrast, oral
glucose-lowering agent use was higher in the youngest group at
46% vs 29% in the oldest group. In addition, antihypertensive
agent use was considerably lower in the youngest group at 23%
vs 80% in the oldest group. Considerably more of the younger
cohort were from countries outside Europe. Men had higher
Table 1. Baseline descriptive statistics stratified by age groups.
Variable Missing data,
n (%)
Overall 18–44 years of
age
45–59 years of
age
60–74 years of
age
≥75 years of
age
n 100,606 8642 30,907 45,269 15,788
Follow-up time (years) 2.8 (2.5) 2.5 (2.5) 2.9 (2.6) 2.9 (2.5) 2.7 (2.3)
Sex, women 0 (0.0) 44,925 (44.7) 3442 (39.8) 11,695 (37.8) 19,865 (43.9) 9923 (62.9)
Age (years) 0 (0.0) 62.0 (12.3) 38.3 (5.6) 53.1 (4.2) 66.2 (4.1) 80.4 (4.4)
HbA1c 8208 (8.2)
mmol/mol 49.2 (11.0) 51.5 (14.6) 50.4 (12.3) 48.2 (9.7) 48.5 (9.4)
% 6.7 (1.0) 6.9 (1.3) 6.8 (1.1) 6.6 (0.9) 6.6 (0.9)
>53 mmol/mol 16, 462 (17.6) 1782 (32.4) 6001 (28.0) 6360 (20.0) 2319 (20.8)
BMI (kg/m2) 25,701 (25.5) 30.6 (5.7) 33.4 (7.3) 31.5 (5.8) 30.2 (5.2) 28.3 (4.7)
BMI >30 kg/m2 25,701 (25.5) 36,437 (48.6) 4131 (65.3) 12,964 (55.7) 15,753 (46.3) 3589 (31.9)
SBP (mmHg) 18,480 (18.4) 137.3 (17.3) 128.4 (15.3) 134.9 (16.5) 139.1 (16.9) 141.6 (18.3)
Systolic hypertension (>140 mmHg) 18,480 (18.4) 26,766 (32.6) 982 (14.8) 6737 (26.9) 13,502 (36.2) 5545 (42.0)
DBP (mmHg) 18,480 (18.4) 79.7 (10.0) 80.5 (10.5) 82.0 (9.9) 79.4 (9.6) 75.6 (9.8)
Diastolic hypertension (>90 mmHg) 18,480 (18.4) 7918 (9.6) 809 (12.2) 3494 (14.0) 3109 (8.3) 506 (3.8)
Total cholesterol (mmol/l) 33,648 (33.4) 5.3 (1.2) 5.3 (1.2) 5.4 (1.2) 5.2 (1.1) 5.1 (1.1)
Hypercholesterolaemia (>6.2 mmol/l) 33,648 (33.4) 12,208 (18.2) 939 (17.7) 4401 (20.8) 5519 (17.6) 1349 (14.8)
LDL-cholesterol (mmol/l) 42,691 (42.4) 3.1 (1.0) 3.2 (1.0) 3.2 (1.0) 3.1 (1.0) 3.0 (1.0)
HDL-cholesterol (mmol/l) 40,893 (40.6) 1.2 (0.4) 1.1 (0.3) 1.2 (0.4) 1.3 (0.4) 1.3 (0.4)
Triacylglycerol (mmol/l) 40,037 (39.8) 2.0 (1.4) 2.4 (1.8) 2.2 (1.6) 1.9 (1.2) 1.7 (0.9)
Microalbuminuriaa 51,166 (50.9) 6110 (12.4) 492 (11.6) 1820 (11.6) 2732 (12.2) 1066 (15.1)
eGFR (ml/min) 22,951 (22.8) 84.8 (25.2) 105.8 (26.9) 93.5 (25.3) 81.8 (21.1) 67.0 (19.9)
Smoker 22,205 (22.1) 14,257 (18.2) 1540 (24.1) 6117 (25.2) 5875 (16.5) 725 (5.9)
Medication useb
Antihypertensive agents 7845 (7.8) 57,686 (62.2) 1801 (23.1) 14,499 (51.2) 29,630 (70.5) 11,756 (80.4)
Statins 7927 (7.9) 35,582 (38.4) 1285 (16.3) 9575 (33.6) 19,029 (45.4) 5693 (39.5)
No medication 0 (0.0) 52,491 (52.2) 3824 (44.2) 14,094 (45.6) 24,533 (54.2) 10,040 (63.6)
Oral glucose-lowering agents 0 (0.0) 38,582 (38.3) 3973 (46.0) 13,197 (42.7) 16,894 (37.3) 4518 (28.6)
Insulin 0 (0.0) 5589 (5.6) 525 (6.1) 2031 (6.6) 2194 (4.8) 839 (5.3)
Insulin + oral glucose-lowering agents 0 (0.0) 3944 (3.9) 320 (3.7) 1585 (5.1) 1648 (3.6) 391 (2.5)
Marital status 448 (0.4)
Single 18,283 (18.3) 4099 (47.5) 8155 (26.5) 5212 (11.6) 817 (5.2)
Married 53,276 (53.2) 3587 (41.6) 15,933 (51.7) 26,678 (59.2) 7078 (45.3)
Separated 17,917 (17.9) 910 (10.5) 6194 (20.1) 9042 (20.1) 1771 (11.3)
Widowed 10,682 (10.7) 35 (0.4) 549 (1.8) 4152 (9.2) 5946 (38.1)
Country of birth 0 (0.0)
Sweden 81,545 (81.1) 5839 (67.6) 23,267 (75.3) 38,412 (84.9) 14,027 (88.8)
Europe (excl. Sweden) 10,612 (10.5) 710 (8.2) 3441 (11.1) 5047 (11.1) 1414 (9.0)
Rest of world 8449 (8.4) 2093 (24.2) 4199 (13.6) 1810 (4.0) 347 (2.2)
Education 1881 (1.9)
Elementary school 36,743 (37.2) 1881 (22.2) 8099 (26.5) 17,687 (39.8) 9076 (59.6)
College level 44,029 (44.6) 4719 (55.8) 15,862 (51.9) 18,939 (42.6) 4509 (29.6)
Upper/secondary school 17,953 (18.2) 1858 (22.0) 6617 (21.6) 7827 (17.6) 1651 (10.8)
All data are based on the first observation after diagnosis, except for HbA1c where the first observation 1 year after diagnosis was used
All continuous variables are represented as mean (SD). Dichotomous variables are represented as number of individuals (%).
aMicroalbuminuria was defined as two positive results for three samples obtained within 1 year of each other, with an albumin/creatinine ratio of 3–30
mg/mmol or a urinary albumin clearance of 20–200 μg/min
b Initial medication data were obtained within 3 months of diagnosis
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HbA1c levels at diagnosis compared with women, but women
had higher BMI (ESM Table 2).
Risk factor trajectories The trajectories of cardiometabolic risk
factors over time by age at type 2 diabetes diagnosis are pre-
sented in Fig. 1. The significantly (p < 0.05) higher BMI level
observed in the youngest age group at diagnosis was sustained
over time relative to the other groups (Fig. 1a). A widening
and significant (p < 0.05) difference in HbA1c was observed
over time, with a difference of ~5mmol/mol (0.45%) at 8 years
between the youngest vs two oldest age groups (Fig. 1b).
Lipid levels remained significantly (p < 0.05) different be-
tween age groups, with the youngest group showing continu-
ally higher triacylglycerol levels (by ~0.5–0.6 mmol/l) com-
pared with the two oldest age groups, and lower HDL-
cholesterol levels compared with all other age groups (al-
though this latter difference narrowed over time) (Fig. 1c,d).
The differences in LDL-cholesterol levels between age groups
widened over time; even though levels in all groups declined
this widening probably reflects more frequent use of statins in
the older age groups (Fig. 1e).
In summary, individuals that developed type 2 diabetes at a
younger age had greater aggregated exposure (i.e. AUC) to
higher BMI, higher blood glucose levels and abnormal lipids
compared with those who developed diabetes at an older age.
Other risk factors (including BP, renal function, total cho-
lesterol and albuminuria) also changed over time (ESM
Fig. 1a–e), but most were as expected. The use of statins and
antihypertensive agents was lowest in the youngest age group
at diagnosis and this was sustained, at least in the early years
following diagnosis (ESM Fig. 1f,g). Finally, number of cur-
rent smokers was highest in the youngest age group and this
did not change over time (ESM Fig. 1h).
Sensitivity analyses in individuals with at least 5 years follow-
up When we restricted analyses to only include individuals
with at least 5 years follow-up and adjusted for key confounders
for each of the main risk factors as depicted in ESMTable 1, the
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Fig. 1 Yearly averages (95% CI)
stratified by age group for (a)
BMI, (b) HbA1c, (c)
triacylglycerol, (d) HDL-
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findings were broadly similar to those reported for the entire
cohort with unadjusted analyses (see ESM Fig. 2a–e). For ex-
ample, the trajectory of blood glucose levels after the first year
was significantly (p < 0.05) greater in the youngest group rela-
tive to the older groups, leading to the highest blood glucose
levels observed in this group at year 6, despite adjustment for
diabetes medication and BMI. Likewise, differences in lipid
abnormalities persisted despite adjustment for sex, BMI and
lipid-lowering therapy. Further analyses adjusting for marital
status, education and country of birth did not materially change
the pattern of results (ESM Fig. 3a–e).
Discussion
To the best of our knowledge, this study of 100,606 individ-
uals with newly diagnosed type 2 diabetes is the largest and
perhaps the first to compare in detail trajectories on several
cardiometabolic risk factors between individuals with type 2
diabetes grouped according to age of diagnosis in a European
(white) population, complementing and extending data from a
recent study in China [19]. The results from our study show
that age at diagnosis of type 2 diabetes is an important aspect
of risk factor control with regard to adiposity, blood glucose
and lipid levels; these factors were all worse in individuals
diagnosed at a younger age and throughout the early years
following diagnosis, during which the use of glucose-
lowering medication was higher in this group relative to older
individuals. Moreover, such differences appear not to be
accounted for by obvious confounders including differential
drug therapy rates, sex, smoking and, where relevant, BMI
differences by age group. The results were also maintained
when we adjusted for socioeconomic variables and, in partic-
ular, country of birth. Therefore, our findings support the no-
tion that early-onset type 2 diabetes may be a more pathogenic
condition per se than later-onset type 2 diabetes, helping to
explain the observation of greater life-years lost when diabetes
is diagnosed at a younger age, as recently reported [20, 21].
Our data on the relationship between age at diagnosis and
cardiometabolic risk factors meaningfully extend previous stud-
ies [22, 23] as it is contemporary and multiple-fold larger in
terms of size. Our results also hold potential clinical relevance.
With respect to hyperglycaemia, despite a higher rate of glucose-
lowering agent use in younger (i.e. ≤45 years of age) compared
with older individuals (Table 1), younger individuals had higher
HbA1c levels and worse trajectories over time, so their aggregat-
ed exposure to hyperglycaemia is worse from the point of diag-
nosis (and potentially prior to diagnosis if diagnosed later).
Therefore, total exposure to hyperglycaemia is clearly higher in
younger individuals and, since hyperglycaemia is a strong and
independent predictor for microvascular complications and has
long-term consequences for CVD in individuals with type 2
diabetes [13, 24, 25], the risk of complications driven in part
by hyperglycaemia should be higher in this group. Younger in-
dividuals may experience delayed diabetes diagnoses owing to a
lower likelihood of opportunistic screening, but the poorer
HbA1c trajectories observed in this group despite similar or great-
er prescription rates for glucose-lowering medications suggest
that undertreatment is unlikely to be the only reason for poor
glycaemic control over time. Clearly, younger individuals are
more frequently obese and their aggregated BMI over time is
higher than in older individuals, which is possibly related to
higher blood glucose levels over time; however, our sensitivity
analyses suggest that blood glucose levels remain higher in the
younger group evenwith adjustment for BMI (ESMFig. 2b) and
with adjustment for other factors including country of birth
(ESM Fig. 3b). Of course, genetic factors may also be of greater
importance for early-onset type 2 diabetes.
Dyslipidaemia, characterised by low HDL-cholesterol and
elevated triacylglycerol levels, is a risk factor for CVD [25]. In
this study, younger individuals had lower HDL-cholesterol
levels and higher triacylglycerol levels at diagnosis, in accor-
dance with most previous studies [22, 23, 26]; although Hillier
et al, in a much smaller study, did not observe a difference in
triacylglycerol levels between individuals with early-onset and
later-onset type 2 diabetes [23].Whilst recent evidence indicates
that higher triacylglycerol levels are causally linked to CVD
[27], other strong evidence indicates earlier hyperlipidaemia
(as measured by either LDL-cholesterol or non-HDL-cholester-
ol—also higher in younger individuals in the present study) is
associated with long-term harm [28]. These collective findings
broadly concur with greater obesity in younger individuals,
although, once again, lipid differences remained with adjust-
ments for BMI and lipid-lowering therapy use, which was low-
er in younger individuals in the early years following diagnosis
and did not catch up with older groups for at least several years.
This is notable since these younger individuals may have more
to profit from preventive treatments, such as statins, in terms of
gain of life-years free from CVD events [29].
The poorer BMI, HbA1c and lipid profiles observed in the
younger individuals helps to explain why early-onset type 2
diabetes may confer a very high lifetime risk of CVD and
premature death compared with later-onset disease [13, 19,
30]. It is clear that the relative hazard of developing CVD is
much greater in individuals with early-onset than later-onset
disease, compared with age-matched individuals without dia-
betes [7]. There have been increasing calls [29, 31] for earlier
treatment of cardiometabolic risk factors for individuals with
high lifetime risks of CVD to enhance survival benefits; youn-
ger individuals with type 2 diabetes fit these criteria well.
The strength of this study is that it is a nationwide study
which included virtually all individuals with newly diagnosed
type 2 diabetes in Sweden within the study period, and is thus
representative of the general diabetes population. This is in
contrast to smaller observational studies. However, we fully
accept some, often inevitable, limitations. For example, our
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study only included Swedish nationals; whilst our results
should be relevant to many high-income countries with high
proportions of individuals of European descent, our work needs
to be replicated in other ethnic groups.We also recognise that the
overall mean length of follow-up was modest, but note that the
same trendswere observed in individualswho had at least 5 years
of follow-up (ESMFig. 2a–e). In addition, we cannot rule out the
probability of missing BMI values from individuals with normal
or close to normal BMI because these individuals may be less
likely to have their BMI recorded, which could lead to a potential
bias that would in fact underestimate, rather than overestimate,
diagnosis-related BMI differentials by age, as well as changes in
BMI over time. However, our BMI data fit well with recent
findings in a Scottish diabetes dataset, lending some external
validity [32]. Finally, we acknowledge that higher HbA1c levels
at diagnosis in younger individuals is due, in part, to a greater
delay in diagnosis compared with older individuals, perhaps be-
cause younger individuals are less likely to be captured by op-
portunistic screening. However, blood glucose levels remained
higher over time, even after diagnosis, in those under 45 years of
age (despite more of this group being on glucose-lowering ther-
apy), potentially suggesting some innate contribution to higher
risk blood glucose profiles.
In summary, individuals with early-onset type 2 diabetes are
more obese at diagnosis and for several years afterwards, have
higher blood glucose levels, and a faster deterioration of
glycaemic control following 1 year of diagnosis compared with
individuals diagnosed at an older age. They also have more
atherogenic lipid profiles. Since such differences remained with
adjustment for obvious confounders, including, where relevant,
glucose- or lipid-lowering treatments and country of birth, our
results support the notion that early-onset type 2 diabetes is a
more pathogenic condition than later-onset disease. Irrespective
of the reasons for worse adiposity, lipid and glycaemic risk factor
profiles in the younger age group, these real-life data suggest a
need for more aggressive management of type 2 diabetes in
younger individuals to lessen life-years lost in this high-risk
group.
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